The human genome sequencing project provides the foundation for using individual genetics to optimize the selection and dosing of medications. The field of pharmacogenomics is still young, but has undergone a revolution in the last decade, as genomic technologies have uncovered associations between drug response phenotypes and genetic variations. The challenge now is to define the mechanisms underlying these associations, to advance our detailed understanding of the genetics of drug response. The PharmGKB (www.pharmgkb.org/) is devoted to collecting, encoding and disseminating knowledge about pharmacogenomics. PharmGKB is the pre-eminent resource for information about genes involved in the pharmacokinetics (PK) and pharmacodynamics of drug response, the pathways in which they act, and their important polymorphisms. PharmGKB staff curate this information, and have also helped lead successful international data sharing initiatives. In this proposal, we outline a plan to (1) curate information about genetic variations, pathways and networks relevant to drug response (2) create informatics tools for understanding the mechanism of drug response, (3) create and support new data sharing consortia, (4) engage in strategic collaborations to maximize PharmGKB's impact, and (5) disseminate the PharmGKB resources to the scientific community. We provide testimonials from users and letters of support from the research community to demonstrate our ongoing impact on the field.
Pharmacogenomics is the study of how variations in human genes affect our response to drugs. It is the science behind personalized medicine-using individual genetics to increase the efficacy of drugs, and reduce their unwanted side effects. This proposal outlines a plan to extend the PharmGKB, a web-based resource that provides high-quality information and tools to researchers in pharmacogenomics.
|Klein, Teri E; Ritchie, Marylyn D (2017) PharmCAT: A Pharmacogenomics Clinical Annotation Tool. Clin Pharmacol Ther :|
|Luzum, J A; Pakyz, R E; Elsey, A R et al. (2017) The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther 102:502-510|
|Relling, M V; Krauss, R M; Roden, D M et al. (2017) New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine. Clin Pharmacol Ther 102:897-902|
|Barbarino, Julia M; Owusu Obeng, Aniwaa; Klein, Teri E et al. (2017) PharmGKB summary: voriconazole pathway, pharmacokinetics. Pharmacogenet Genomics 27:201-209|
|Fohner, Alison E; McDonagh, Ellen M; Clancy, John P et al. (2017) PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics 27:39-42|
|Bell, G C; Caudle, K E; Whirl-Carrillo, M et al. (2017) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 102:213-218|
|Gong, Li; Giacomini, Marilyn M; Giacomini, Craig et al. (2017) PharmGKB summary: sorafenib pathways. Pharmacogenet Genomics 27:240-246|
|Gaedigk, Andrea; Sangkuhl, Katrin; Whirl-Carrillo, Michelle et al. (2017) Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 19:69-76|
|Johnson, J A; Caudle, K E; Gong, L et al. (2017) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther 102:397-404|
|Gottlieb, Assaf; Daneshjou, Roxana; DeGorter, Marianne et al. (2017) Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans. Genome Med 9:98|
Showing the most recent 10 out of 154 publications